{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-102285","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2021-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.669466+00:00","generated_at":"2026-06-29T18:39:35.511900+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Twist Bioscience appoints drug discovery leader Melissa Starovasnik to board","bullets":["Dr. Starovasnik appointed to board effective Aug 5, 2021; will receive $40k cash retainer (pro rata) and $340k in equity vesting over 3 years.","She spent nearly 30 years at Genentech, most recently as Senior Scientific Advisor, leading protein therapeutics discovery.","Kevin Yankton appointed principal accounting officer; previously Chief Accounting Officer at Varex Imaging; James Thorburn remains CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-102285","json":"https://secwatch.observer/filing/0001104659-21-102285.json","markdown":"https://secwatch.observer/filing/0001104659-21-102285.md","text":"https://secwatch.observer/filing/0001104659-21-102285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921102285/0001104659-21-102285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921102285/tm2124344d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T18:39:35.511900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55b8389404","claim":"Melissa Starovasnik was elected as Director at Twist Bioscience Corp.","evidence_excerpt":"On August 5, 2021, the Board of Directors (the “ Board ”) of Twist Bioscience Corporation (the “ Company ”) elected Dr. Melissa Starovasnik to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921102285/0001104659-21-102285-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bf8a7d62b7","claim":"Kevin Yankton was appointed as principal accounting officer at Twist Bioscience Corp.","evidence_excerpt":"On August 5, 2021, Board appointed Kevin Yankton, the Company’s Chief Accounting Officer, as principal accounting officer, effective August 5, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921102285/0001104659-21-102285-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"ebedaa33f9","claim":"James Thorburn changed role as principal accounting officer at Twist Bioscience Corp.","evidence_excerpt":"James Thorburn, the Company’s Chief Financial Officer, previously served as principal accounting officer and will continue to serve as Chief Financial Officer and principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921102285/0001104659-21-102285-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}